checkAd

     517  0 Kommentare The Life Sciences Report Examines How 3D Signatures' TeloView Can Diagnose Alzheimer's with a Cheek Swab - Seite 2

    Commenting on the news, Knight Therapeutics CEO and president Jonathan Goodman stated, "Knight is delighted with its investment in 3D Signatures on multiple dimensions. One example is 3D Signatures' progress in Alzheimer's disease, including the company's ability to detect the presence and severity of the disease in living patients from a simple cheek swab. If validated through additional research, this could be a game-changer for AD diagnosis and the development of effective treatments."

    Knight has provided "capital to advance the development of [3D Signatures'] novel diagnostic and prognostic technologies," according to a press release from December 2016.

    "The search for sensitive and noninvasive markers to detect Alzheimer's has been a hot topic lately," Magdalena Kegel wrote in an article for Alzheimer's News Today about the 3D Signatures announcement. "For now, scientists can only make a definitive diagnosis of Alzheimer's after death, and amyloid plaques are detected in a patient's brain. And although current imaging methods can detect the Alzheimer's protein in the brains of living people, doctors don't consider this method practical for routine screening."

    Given the large unmet medical need, the growing demographics of people susceptible to developing Alzheimer's, and consequently the large market opportunity, a number of large pharmaceutical firms are looking for an Alzheimer's treatment and/or cure. According to an article in PharmaExec.com, research firm GlobalData anticipates "The global market for Alzheimer's Disease (AD) treatment will more than double in value from $4.9 billion in 2013 to reach an estimated $13.3 billion by 2023."

    Continue reading this article: 3D Signatures' TeloView Can Diagnose Alzheimer's with Cheek Swab

    About Streetwise Reports - The Life Sciences Report

    Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

    DISCLOSURE:

    3D Signatures Inc. is a billboard sponsor of Streetwise Reports. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor's fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

    Please see the end of the article for the complete disclosure: 3D Signatures' TeloView Can Diagnose Alzheimer's with Cheek Swab

    Contact Information:
    Carrie Beal Amaro
    Associate Publisher
    Email contact

    Seite 2 von 2




    Verfasst von Marketwired
    The Life Sciences Report Examines How 3D Signatures' TeloView Can Diagnose Alzheimer's with a Cheek Swab - Seite 2 SAN FRANCISCO, CA--(Marketwired - March 31, 2017) - With a swab taken from the inside of a patient's cheek, 3D Signatures Inc.'s (TSX VENTURE: DXD) (OTCQB: TDSGF) TeloView platform has demonstrated its ability to diagnose Alzheimer's disease, and …